Updated August 30, 2013, at 4:00 p.m. with comments from Stryker.
The FDA issued a Class I recall for 5 lots of Stryker Spine’s Oasys Midline Occipital Plate, warning patients and physicians that the device might fracture after surgery.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Welcome to MassDevice's Orthopedics Hub, your resource for the latest in orthopedic news. Stay informed about the innovations and business news shaping the ortho device industry.
🦴 Narrow your focus with these categories:
Implants | Metal-on-Metal | Spine
Here are the top orthopedic device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ The biggest stories from AAOS 2024
+ The 10 largest orthopedic device companies in the world
+ The ZimVie Tether helps kids with scoliosis — if they can get it in time
+ Could 2023 be a boom year for orthopedic devices?
+ The top orthopedic device news out of AAOS 2023
🎙️ Tune in to the Ortho Innovation Talks podcast on the DeviceTalks podcast network.
Updated August 30, 2013, at 4:00 p.m. with comments from Stryker.
The FDA issued a Class I recall for 5 lots of Stryker Spine’s Oasys Midline Occipital Plate, warning patients and physicians that the device might fracture after surgery.
Tissue Regeneration Systems won FDA clearance for its 3D-printed Cranial Bone Void Filler, the flagship product in a suite of devices indicated for cranial reconstruction.
Designed to fill holes left behind after surgery, the CBV filler appears to be the 1st 3D-printed device of its kind to get the FDA’s green light for the U.S. market.
Carlsbad, Calif.-based Aurora Spine is hoping to round up as much as $3.6 million through an initial public offering, launched today, through which the company is issuing nearly 5.2 million shares at a per-share price of 70¢.
LDR Holding Corp. announced that it’s making a bid for its initial public offering, aiming to sell its stock on the NASDAQ global market under the stock ticker ‘LDRH’, according to a company statement.
The company Texas-based spinal device company did not disclose the number of shares or detailed pricing for the IPO, but filed for an offering of up to $69 million, SEC documents show.
Biomet will go to bat over its M2A-magnum metal-on-metal hip implants after failing to convince an Indiana federal judge that a personal injury lawsuit was preempted by FDA rules.
By Jeffrey Binder
On August 4, the New York Times ran the latest installment in its series on healthcare costs in the U.S. titled "In Need of a New Hip, but Priced Out of the U.S."
Two Biomet subsidiaries are on the hook for some $2.7 million in royalty payments to a prominent spine surgeon it stopped paying in 2008, after a New Jersey appeals court upheld a lower court’s ruling in Dr. Neil Kahanovitz’s favor.
The societal and economic savings of knee replacement surgery outweigh its costs nearly 2-fold, according to an American Academy of Orthopaedic Surgeons study.